These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 30803159)

  • 1. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections.
    Hengzhuang W; Green K; Pressler T; Skov M; Katzenstein TL; Wu X; Høiby N
    Pediatr Pulmonol; 2019 May; 54(5):575-580. PubMed ID: 30803159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.
    Pompilio A; Crocetta V; Pomponio S; Fiscarelli E; Di Bonaventura G
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):318-25. PubMed ID: 26004353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.
    Hengzhuang W; Wu H; Ciofu O; Song Z; Høiby N
    Antimicrob Agents Chemother; 2012 May; 56(5):2683-90. PubMed ID: 22354300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients.
    Sans-Serramitjana E; Fusté E; Martínez-Garriga B; Merlos A; Pastor M; Pedraz JL; Esquisabel A; Bachiller D; Vinuesa T; Viñas M
    J Cyst Fibros; 2016 Sep; 15(5):611-8. PubMed ID: 26708265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-biofilm activity of murepavadin against cystic fibrosis Pseudomonas aeruginosa isolates.
    Díez-Aguilar M; Ekkelenkamp M; Morosini MI; Huertas N; Del Campo R; Zamora J; Fluit AC; Tunney MM; Obrecht D; Bernardini F; Cantón R
    J Antimicrob Chemother; 2021 Sep; 76(10):2578-2585. PubMed ID: 34283223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.
    Pritchard MF; Powell LC; Jack AA; Powell K; Beck K; Florance H; Forton J; Rye PD; Dessen A; Hill KE; Thomas DW
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of
    Valzano F; Boncompagni SR; Micieli M; Di Maggio T; Di Pilato V; Colombini L; Santoro F; Pozzi G; Rossolini GM; Pallecchi L
    Microbiol Spectr; 2022 Aug; 10(4):e0100622. PubMed ID: 35735984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions.
    Kolpen M; Appeldorff CF; Brandt S; Mousavi N; Kragh KN; Aydogan S; Uppal HA; Bjarnsholt T; Ciofu O; Høiby N; Jensen PØ
    Pathog Dis; 2016 Feb; 74(1):ftv086. PubMed ID: 26458402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Conole D; Keating GM
    Drugs; 2014 Mar; 74(3):377-87. PubMed ID: 24510624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
    Hodson ME; Gallagher CG; Govan JR
    Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
    Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
    Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the spatiotemporal dependence of
    Sans-Serramitjana E; Jorba M; Pedraz JL; Vinuesa T; Viñas M
    Int J Nanomedicine; 2017; 12():4409-4413. PubMed ID: 28652741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
    Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
    J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
    Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS
    Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
    Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.
    Cheah SE; Wang J; Nguyen VT; Turnidge JD; Li J; Nation RL
    J Antimicrob Chemother; 2015 Dec; 70(12):3291-7. PubMed ID: 26318190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model.
    Hengzhuang W; Song Z; Ciofu O; Onsøyen E; Rye PD; Høiby N
    Antimicrob Agents Chemother; 2016 May; 60(5):2620-6. PubMed ID: 26833153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa.
    Lu Q; Girardi C; Zhang M; Bouhemad B; Louchahi K; Petitjean O; Wallet F; Becquemin MH; Le Naour G; Marquette CH; Rouby JJ
    Intensive Care Med; 2010 Jul; 36(7):1147-55. PubMed ID: 20397007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.